Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study – Click here to read more.
Objective To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients. Methods A systematic…
What is Known and the Objective High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration of their real-world costs and cost-effectiveness is often required for reimbursement….
Read our publication on the Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.
Review our publication on “End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?”.
Summary Due to the disease heterogeneity, treatments for chronic lymphocytic leukemia (CLL) have differed with respect to efficacy and toxicity. Limited options have also been available regarding modalities of administration….
Review our publication on “Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial.”
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Read the full article now!
Review our publication on “A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer.”
Read our publication on “Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom.”